Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer

ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), today announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in...
January 20, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

ROCKVILLE, Md., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
January 03, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017

ROCKVILLE, Md., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of...
November 07, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology (ESMO) Congress Initiates Stage 2 of the...
October 31, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent

ROCKVILLE, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
October 26, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors

Rexahn’s proprietary nanotechnology drug conjugate platforms optimize chemotherapy effectiveness and reduce side effect liability ROCKVILLE, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Rexahn...
October 10, 2016 07:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective Supinoxin™ was Safe and Well Tolerated in Patients with Advanced...
October 04, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
September 14, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Announces $6 Million Registered Direct Offering

ROCKVILLE, Md., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into a definitive agreement with institutional investors to purchase...
September 12, 2016 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patients for Whom Three Prior Therapies had been Ineffective RX-3117 was Safe and Well Tolerated Results Have Been...